Medy-Tox Inc

Based on integrity and open communication, Medytox is building excellent capacity
and system to meet the global standard with commitment and courage.
Furthermore, we are endeavoring to reach $1 billion in sales, $10 billion in market value,
and to become one of the world's top 20 biopharmaceutical companies

Since the launch of botulinum toxin type A Meditoxin® in 2006 (trade name: Neuronox®, Siax®, Botulift®, Cunox®, Acebloc® and Meditoxin®), Medytox has shown a dramatic growth. Medytox reached nearly 40% of market share in Korea since 2009 and is expected to increase even further with various indications being included.
Medytox is stunning the world with high market share in the global botulinum market. With the goal of penetrating to the US and Europe, we plan to exceed 10% of the market share in the global market along with the launch of the currently developing new type botulinum toxin products. In the future, Medytox will grow as the leader of the biopharmaceutical industry by challenging ourselves with passion for the global market.